id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-1518-0017,FDA,FDA-2020-D-1518,Development of Anti-Infective Drug Products for the Pediatric Population Guidance for Industry,Other,Guidance,2021-12-10T05:00:00Z,2021,12,2021-12-10T05:00:00Z,,2024-11-12T23:35:57Z,,1,0,0900006484eb8f75
FDA-2020-D-1518-0016,FDA,FDA-2020-D-1518,Development of Anti-Infective Drug Products for the Pediatric Population; Guidance for Industry; Availability,Notice,Notice of Availability,2021-12-10T05:00:00Z,2021,12,2021-12-10T05:00:00Z,,2021-12-10T13:30:21Z,2021-26737,0,0,0900006484eb7f61
FDA-2020-D-1518-0002,FDA,FDA-2020-D-1518,"Development of Anti-Infective Drug Products for the Pediatric Population;
Guidance for Industry; Draft Guidance",Other,Guidance,2020-06-30T04:00:00Z,2020,6,2020-06-30T04:00:00Z,,2024-11-12T23:22:37Z,,1,0,090000648471c186
FDA-2020-D-1518-0001,FDA,FDA-2020-D-1518,Development of Anti-Infective Drug Products for the Pediatric Population; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2020-06-30T04:00:00Z,2020,6,2020-06-30T04:00:00Z,2020-09-01T03:59:59Z,2020-09-01T01:01:37Z,2020-14085,0,0,090000648471b01b